drugset / Trial / NCT03758287
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
Timeline
- Start
- 2016-11
- Primary completion
- 2021-09-17
- Completion
- 2021-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT053PTSA | Unknown | 30 mg | Oral |
| Subject | CT053PTSA | Unknown | 40 mg | Oral |
| Subject | CT053PTSA | Unknown | 60 mg | Oral |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |